Product Description
GE-200486 is a MRI contrast imaging agents being developed by GE Healthcare. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05569278?term=GE-200486&draw=2&rank=1)
Mechanisms of Action: Contrast Agent
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GE Healthcare
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| GE-227-001 | P1 |
Completed |
Healthy Volunteers |
2022-11-29 |
50% |
2023-01-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|